Literature DB >> 28096240

Coevolution of Leukemia and Host Immune Cells in Chronic Lymphocytic Leukemia.

Noelia Purroy1,2,3, Catherine J Wu1,2,3,4.   

Abstract

Cumulative studies on the dissection of changes in driver genetic lesions in cancer across the course of the disease have provided powerful insights into the adaptive mechanisms of tumors in response to the selective pressures of therapy and environmental changes. In particular, the advent of next-generation-sequencing (NGS)-based technologies and its implementation for the large-scale comprehensive analyses of cancers have greatly advanced our understanding of cancer as a complex dynamic system wherein genetically distinct subclones interact and compete during tumor evolution. Aside from genetic evolution arising from interactions intrinsic to the cell subpopulations within tumors, it is increasingly appreciated that reciprocal interactions between the tumor cell and cellular constituents of the microenvironment further exert selective pressures on specific clones that can impact the balance between tumor immunity and immunologic evasion and escape. Herein, we review the evidence supporting these concepts, with a particular focus on chronic lymphocytic leukemia (CLL), a disease that has been highly amenable to genomic interrogation and studies of clonal heterogeneity and evolution. Better knowledge of the basis for immune escape has an important clinical impact on prognostic stratification and on the pursuit of new therapeutic opportunities.
Copyright © 2017 Cold Spring Harbor Laboratory Press; all rights reserved.

Entities:  

Mesh:

Year:  2017        PMID: 28096240      PMCID: PMC5378011          DOI: 10.1101/cshperspect.a026740

Source DB:  PubMed          Journal:  Cold Spring Harb Perspect Med        ISSN: 2157-1422            Impact factor:   6.915


  185 in total

Review 1.  Novel insights in chronic lymphocytic leukemia: are we getting closer to understanding the pathogenesis of the disease?

Authors:  Federico Caligaris-Cappio; Paolo Ghia
Journal:  J Clin Oncol       Date:  2008-07-28       Impact factor: 44.544

2.  CD57+/CD28- T cells in untreated hemato-oncological patients are expanded and display a Th1-type cytokine secretion profile, ex vivo cytolytic activity and enhanced tendency to apoptosis.

Authors:  L E Van den Hove; S W Van Gool; P Vandenberghe; M A Boogaerts; J L Ceuppens
Journal:  Leukemia       Date:  1998-10       Impact factor: 11.528

Review 3.  Unique tumor antigens: evidence for immune control of genome integrity and immunogenic targets for T cell-mediated patient-specific immunotherapy.

Authors:  Marialuisa Sensi; Andrea Anichini
Journal:  Clin Cancer Res       Date:  2006-09-01       Impact factor: 12.531

4.  A comprehensive catalogue of somatic mutations from a human cancer genome.

Authors:  Erin D Pleasance; R Keira Cheetham; Philip J Stephens; David J McBride; Sean J Humphray; Chris D Greenman; Ignacio Varela; Meng-Lay Lin; Gonzalo R Ordóñez; Graham R Bignell; Kai Ye; Julie Alipaz; Markus J Bauer; David Beare; Adam Butler; Richard J Carter; Lina Chen; Anthony J Cox; Sarah Edkins; Paula I Kokko-Gonzales; Niall A Gormley; Russell J Grocock; Christian D Haudenschild; Matthew M Hims; Terena James; Mingming Jia; Zoya Kingsbury; Catherine Leroy; John Marshall; Andrew Menzies; Laura J Mudie; Zemin Ning; Tom Royce; Ole B Schulz-Trieglaff; Anastassia Spiridou; Lucy A Stebbings; Lukasz Szajkowski; Jon Teague; David Williamson; Lynda Chin; Mark T Ross; Peter J Campbell; David R Bentley; P Andrew Futreal; Michael R Stratton
Journal:  Nature       Date:  2009-12-16       Impact factor: 49.962

5.  CD38/CD31, the CCL3 and CCL4 chemokines, and CD49d/vascular cell adhesion molecule-1 are interchained by sequential events sustaining chronic lymphocytic leukemia cell survival.

Authors:  Antonella Zucchetto; Dania Benedetti; Claudio Tripodo; Riccardo Bomben; Michele Dal Bo; Daniela Marconi; Fleur Bossi; Debora Lorenzon; Massimo Degan; Francesca Maria Rossi; Davide Rossi; Pietro Bulian; Vito Franco; Giovanni Del Poeta; Silvia Deaglio; Gianluca Gaidano; Francesco Tedesco; Fabio Malavasi; Valter Gattei
Journal:  Cancer Res       Date:  2009-04-21       Impact factor: 12.701

6.  Adaptive immunity maintains occult cancer in an equilibrium state.

Authors:  Catherine M Koebel; William Vermi; Jeremy B Swann; Nadeen Zerafa; Scott J Rodig; Lloyd J Old; Mark J Smyth; Robert D Schreiber
Journal:  Nature       Date:  2007-11-18       Impact factor: 49.962

7.  The DLEU2/miR-15a/16-1 cluster controls B cell proliferation and its deletion leads to chronic lymphocytic leukemia.

Authors:  Ulf Klein; Marie Lia; Marta Crespo; Rachael Siegel; Qiong Shen; Tongwei Mo; Alberto Ambesi-Impiombato; Andrea Califano; Anna Migliazza; Govind Bhagat; Riccardo Dalla-Favera
Journal:  Cancer Cell       Date:  2010-01-07       Impact factor: 31.743

8.  The PD-1/PD-L1 axis contributes to T-cell dysfunction in chronic lymphocytic leukemia.

Authors:  Davide Brusa; Sara Serra; Marta Coscia; Davide Rossi; Giovanni D'Arena; Luca Laurenti; Ozren Jaksic; Giorgio Fedele; Giorgio Inghirami; Gianluca Gaidano; Fabio Malavasi; Silvia Deaglio
Journal:  Haematologica       Date:  2013-01-08       Impact factor: 9.941

9.  Tumor evolution. High burden and pervasive positive selection of somatic mutations in normal human skin.

Authors:  Iñigo Martincorena; Amit Roshan; Moritz Gerstung; Peter Ellis; Peter Van Loo; Stuart McLaren; David C Wedge; Anthony Fullam; Ludmil B Alexandrov; Jose M Tubio; Lucy Stebbings; Andrew Menzies; Sara Widaa; Michael R Stratton; Philip H Jones; Peter J Campbell
Journal:  Science       Date:  2015-05-22       Impact factor: 47.728

10.  Exposure to Melan-A/MART-126-35 tumor epitope specific CD8(+)T cells reveals immune escape by affecting the ubiquitin-proteasome system (UPS).

Authors:  Frédéric Ebstein; Martin Keller; Annette Paschen; Peter Walden; Michael Seeger; Elke Bürger; Elke Krüger; Dirk Schadendorf; Peter-M Kloetzel; Ulrike Seifert
Journal:  Sci Rep       Date:  2016-05-04       Impact factor: 4.379

View more
  14 in total

Review 1.  Personal tumor antigens in blood malignancies: genomics-directed identification and targeting.

Authors:  Livius Penter; Catherine J Wu
Journal:  J Clin Invest       Date:  2020-04-01       Impact factor: 14.808

2.  Single-cell analysis reveals immune dysfunction from the earliest stages of CLL that can be reversed by ibrutinib.

Authors:  Noelia Purroy; Yuzhou Evelyn Tong; Camilla K Lemvigh; Nicoletta Cieri; Shuqiang Li; Erin M Parry; Wandi Zhang; Laura Z Rassenti; Thomas J Kipps; Susan L Slager; Neil E Kay; Connie Lesnick; Tait D Shanafelt; Paolo Ghia; Lydia Scarfò; Kenneth J Livak; Peter V Kharchenko; Donna S Neuberg; Lars Rønn Olsen; Jean Fan; Satyen H Gohil; Catherine J Wu
Journal:  Blood       Date:  2022-04-07       Impact factor: 25.476

3.  PI3K p110δ inactivation antagonizes chronic lymphocytic leukemia and reverses T cell immune suppression.

Authors:  Shuai Dong; Bonnie K Harrington; Eileen Y Hu; Joseph T Greene; Amy M Lehman; Minh Tran; Ronni L Wasmuth; Meixiao Long; Natarajan Muthusamy; Jennifer R Brown; Amy J Johnson; John C Byrd
Journal:  J Clin Invest       Date:  2018-11-19       Impact factor: 14.808

Review 4.  Order Matters: The Order of Somatic Mutations Influences Cancer Evolution.

Authors:  David G Kent; Anthony R Green
Journal:  Cold Spring Harb Perspect Med       Date:  2017-04-03       Impact factor: 6.915

Review 5.  Dissecting CLL through high-dimensional single-cell technologies.

Authors:  Satyen H Gohil; Catherine J Wu
Journal:  Blood       Date:  2019-02-06       Impact factor: 25.476

6.  LINC00152 expression in normal and Chronic Lymphocytic Leukemia B cells.

Authors:  Serena Matis; Martina Rossi; Lorenzo Brondolo; Martina Cardillo; Daniele Reverberi; Rosanna Massara; Monica Colombo; Adalberto Ibatici; Emanuele Angelucci; Tiziana Vaisitti; Silvia Bruno; Sonia Fabris; Antonino Neri; Massimo Gentile; Fortunato Morabito; Giovanna Cutrona; Paola Briata; Roberto Gherzi; Franco Fais
Journal:  Hematol Oncol       Date:  2021-10-28       Impact factor: 4.850

7.  Circulating T Cell Subpopulations Correlate With Immune Responses at the Tumor Site and Clinical Response to PD1 Inhibition in Non-Small Cell Lung Cancer.

Authors:  Nataly Manjarrez-Orduño; Laurence C Menard; Selena Kansal; Paul Fischer; Bijal Kakrecha; Can Jiang; Mark Cunningham; Danielle Greenawalt; Vishal Patel; Minghui Yang; Ryan Golhar; Julie A Carman; Sergey Lezhnin; Hongyue Dai; Paul S Kayne; Suzanne J Suchard; Steven H Bernstein; Steven G Nadler
Journal:  Front Immunol       Date:  2018-08-03       Impact factor: 7.561

8.  Low-count monoclonal B-cell lymphocytosis persists after seven years of follow up and is associated with a poorer outcome.

Authors:  Ignacio Criado; Arancha Rodríguez-Caballero; M Laura Gutiérrez; Carlos E Pedreira; Miguel Alcoceba; Wendy Nieto; Cristina Teodosio; Paloma Bárcena; Alfonso Romero; Paulino Fernández-Navarro; Marcos González; Julia Almeida; Alberto Orfao
Journal:  Haematologica       Date:  2018-03-22       Impact factor: 9.941

Review 9.  TP53 aberrations in chronic lymphocytic leukemia: an overview of the clinical implications of improved diagnostics.

Authors:  Elias Campo; Florence Cymbalista; Paolo Ghia; Ulrich Jäger; Sarka Pospisilova; Richard Rosenquist; Anna Schuh; Stephan Stilgenbauer
Journal:  Haematologica       Date:  2018-11-15       Impact factor: 9.941

10.  EZN-2208 treatment suppresses chronic lymphocytic leukaemia by interfering with environmental protection and increases response to fludarabine.

Authors:  Roberta Valsecchi; Nadia Coltella; Daniela Magliulo; Lucia Bongiovanni; Lydia Scarfò; Paolo Ghia; Maurilio Ponzoni; Rosa Bernardi
Journal:  Open Biol       Date:  2020-05-13       Impact factor: 6.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.